Aeterna Zentaris to Announce Second Quarter 2018 Financial and Operating Results on August 9, 2018
August 02 2018 - 4:05PM
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS)
will announce its second quarter 2018 financial and operating
results after market close on Thursday, August 9, 2018. The Company
will host a conference call to discuss these results on Friday,
August 10, 2018 at 8:30 a.m. Eastern Time.
Participants may access the conference call by telephone using
the following numbers:
- Toll-Free: 877-407-8029, Confirmation #13681858
- Toll: 201-689-8029, Confirmation #13681858
A replay will also be available on the Company’s website for a
period of 30 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company
focused on developing and commercializing, principally through
out-licensing arrangements, Macrilen™ (macimorelin), an oral
ghrelin receptor agonist, to be administered in the diagnosis of
patients with adult growth hormone deficiency. Aeterna
Zentaris has entered into a license and assignment agreement with a
wholly-owned subsidiary of Strongbridge Biopharma plc to carry out
development, manufacturing, registration and commercialization of
Macrilen™ (macimorelin) in the United States and Canada. For more
information, visit www.zentaris.com.
Contact:
Aeterna Zentaris Inc.James ClavijoChief Financial
OfficerIR@aezsinc.com843-900-3201
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024